Prudential Financial Inc. Decreases Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Prudential Financial Inc. lessened its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 77.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 18,753 shares of the biopharmaceutical company's stock after selling 64,212 shares during the quarter. Prudential Financial Inc.'s holdings in Alnylam Pharmaceuticals were worth $4,413,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. Larson Financial Group LLC grew its stake in shares of Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 73 shares during the period. R Squared Ltd purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter worth $33,000. True Wealth Design LLC grew its position in Alnylam Pharmaceuticals by 15,300.0% during the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 153 shares during the period. OFI Invest Asset Management purchased a new position in Alnylam Pharmaceuticals in the fourth quarter valued at $35,000. Finally, Versant Capital Management Inc raised its position in shares of Alnylam Pharmaceuticals by 77.6% in the fourth quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 83 shares during the period. Hedge funds and other institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Trading Down 10.1 %

Shares of Alnylam Pharmaceuticals stock traded down $26.42 during mid-day trading on Friday, hitting $235.74. The stock had a trading volume of 1,881,579 shares, compared to its average volume of 844,661. The firm has a market cap of $30.67 billion, a P/E ratio of -108.64 and a beta of 0.30. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The firm has a 50-day moving average of $259.03 and a two-hundred day moving average of $260.23. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39.

Remove Ads

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on ALNY shares. Canaccord Genuity Group lifted their price target on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a "buy" rating in a research note on Friday, March 21st. HC Wainwright restated a "buy" rating and issued a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday. Citigroup increased their target price on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a research report on Friday, March 21st. Morgan Stanley boosted their price target on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an "equal weight" rating in a report on Friday, February 14th. Finally, Wells Fargo & Company increased their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an "equal weight" rating in a report on Friday, March 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $316.25.

Insider Activity at Alnylam Pharmaceuticals

In related news, Director Phillip A. Sharp sold 11,250 shares of the business's stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the firm's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the transaction, the executive vice president now owns 14,321 shares of the company's stock, valued at $3,654,862.41. This trade represents a 4.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 71,234 shares of company stock worth $19,958,097. Company insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.